AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05960201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoroestradiol (FES)
Description: F-18 FES 111\~222 MBq(megabecquerel) injection
Study NCT06569095 — intervention group
Intervention type: OTHER
Intervention: Detection of MDS-SC using MFC
Description: The aim of this study is to investigate the predictive values of MDS-SC determined by MFC for patients with MDS-EB who underwent allotransplantation.
Study NCT06186401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-SYNC T Cells
Description: Given IV
Study NCT06186401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (non-investigational)
Description: Given IV
Study NCT06223737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOS x-ray
Description: After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
Study NCT06186401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (non-investigational)
Description: Given IV
Study NCT06223737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EOS x-ray
Description: After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
Study NCT06223737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motion capture
Description: The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand
Study NCT06223737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motion capture
Description: The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand
Study NCT06186401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT06186401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Undergo surgical resection of tumor tissue
Study NCT06496607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug Low Dose
Description: Solrikitug Low Dose subcutaneous injection
Study NCT06496607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug Mid Dose
Description: Solrikitug Mid Dose subcutaneous injection
Study NCT06496607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug High Dose
Description: Solrikitug High Dose subcutaneous injection
Study NCT06496607 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT05103111 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT05758493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 124I-Evuzamitide
Description: Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
Study NCT05488964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
Study NCT06204666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Hemp Fiber Bar
Description: Low dose hemp fiber bar with other ingredients
Study NCT06204666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bar with other ingredients
Study NCT06156007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercises
Description: Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
Study NCT05736367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-13C-glucose
Description: Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
Study NCT06473480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abott FreeStyle Libre System 2
Description: The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
Study NCT06473480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abott Freestyle Libre Pro
Description: The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
Study NCT06481735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell
Description: Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.
Study NCT06481735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.
Study NCT06481735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
Study NCT04988737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Clinical Decision Support Application
Description: Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
Study NCT06109805 — intervention group
Intervention type: OTHER
Intervention: Gastric cancer
Description: Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
Study NCT04970498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
Study NCT04970498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine test
Description: The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
Study NCT05649332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argogen (silver zeolite powder)
Description: The medical device will be self-administered by each patient twice daily without interruption for the duration of the study (4 weeks) or until complete healing. Application is carried out by spraying at short intervals, lightly pressing the dispenser button and directing the spray onto the area to be treated.
Study NCT04859140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychometric ratings (Likert-scale)
Description: Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
Study NCT04859140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric ratings (Likert-scale)
Description: Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
Study NCT04956692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab SC
Description: SC injection
Study NCT04859140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Range of motion measures
Description: Sit-and-reach and toe touch tests
Study NCT04859140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of motion measures
Description: Sit-and-reach and toe touch tests
Study NCT04859140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental calculation task
Description: Iterated substractions (for 2 minutes)
Study NCT04859140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental calculation task
Description: Iterated substractions (for 2 minutes)
Study NCT04859140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resting-state electroencephalography
Description: Alpha and beta oscillation power (4 minutes recordings)
Study NCT04859140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting-state electroencephalography
Description: Alpha and beta oscillation power (4 minutes recordings)
Study NCT04956692 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab IV
Description: IV injection
Study NCT04859140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resting-state galvanic skin resistance measures
Description: Skin conductance during the resting state period
Study NCT04859140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting-state galvanic skin resistance measures
Description: Skin conductance during the resting state period
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV injection
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV injection
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: IV infusion
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: IV infusion
Study NCT05187988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular brachial plexus block
Description: group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
Study NCT05187988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retroclavicular brachial plexus block
Description: group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
Study NCT04893109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab-emtansine
Description: intravenous infusion
Study NCT04893109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC
Description: Muscular injection
Study NCT04893109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion
Study NCT04991935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: CC-93538
Study NCT06152731 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: tests to determine HRD status
Description: Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations
Study NCT05704725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 938
Description: IVT injection
Study NCT05704725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: IVT injection
Study NCT04426812 — intervention group
Intervention type: OTHER
Intervention: No intervention; just data collection
Description: No intervention; just data collection
Study NCT04858997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT04858997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI
Description: AI, orally once daily (continuously)
Study NCT06501105 — intervention group
Intervention type: DEVICE
Intervention: WOUNDCHEK Bacterial Status
Description: Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.
Study NCT06274788 — intervention group
Intervention type: DRUG
Intervention: Omegaven® (fish oil triglycerides) Injectable Emulsion
Description: Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator
Study NCT04829448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: Protein supplement equivalent to Metagenics Ultrameal
Study NCT05247255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: QL block with 0.25% ropivacaine
Study NCT05247255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: QL block with saline
Study NCT05437263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Description: Oral Brepocitinib
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT05355519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic curriculum and instructor-led course, then placebo
Description: Electronic curriculum and instructor-led course
Study NCT05355519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, then electronic curriculum and instructor-led course
Description: Electronic curriculum and instructor-led course
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT04956692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT05437263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study NCT05112991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab+Lenvatinib
Description: Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle.
Study NCT05112991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
Study NCT06572241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: morphine 100 mcg, included in the intrathecal component of combined spinal epidural (CSE).
Study NCT06572241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution (placebo)
Description: normal saline 0.2 ml added to the intrathecal component of combined spinal epidural (CSE).
Study NCT04385732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2D or 3D Melanoma Surveillance Photography
Description: Total body imaging using 2D or 3D Melanoma Surveillance Photography plus digital dermoscopy.
Study NCT05890677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
Study NCT05890677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Complex Physical Decongestion Therapy
Description: Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.
Study NCT04309812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Electrical stimulation of scalp over a seizure focus
Study NCT04309812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Electrical stimulation of scalp over a seizure focus
Study NCT05532475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of vitreous level of tumor necrosis factor alpha
Description: measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
Study NCT05672524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
Study NCT05672524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
Study NCT06479876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBCR
Description: Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
Study NCT06071468 — intervention group
Intervention type: DEVICE
Intervention: UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US)
Description: The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.